68.36
0.25%
-0.17
After Hours:
68.36
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is currently priced at $68.36, with a 24-hour trading volume of 3.98M.
It has seen a -0.25% decreased in the last 24 hours and a +3.81% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $68.51 pivot point. If it approaches the $68.22 support level, significant changes may occur.
Astrazeneca PLC Stock (AZN) Financials Data
Astrazeneca PLC (AZN) Revenue 2024
AZN reported a revenue (TTM) of $45.81 billion for the quarter ending December 31, 2023, a +3.29% rise year-over-year.
Astrazeneca PLC (AZN) Net Income 2024
AZN net income (TTM) was $5.96 billion for the quarter ending December 31, 2023, a +81.17% increase year-over-year.
Astrazeneca PLC (AZN) Cash Flow 2024
AZN recorded a free cash flow (TTM) of $6.57 billion for the quarter ending December 31, 2023, a -9.26% decrease year-over-year.
Astrazeneca PLC (AZN) Earnings per Share 2024
AZN earnings per share (TTM) was $1.915 for the quarter ending December 31, 2023, a +81.52% growth year-over-year.
Astrazeneca PLC Stock (AZN) Latest News
Astrazeneca (AZN) Could Be a Great Choice
Zacks Investment Research
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Benzinga
International Wide-Moat Stocks On Sale - The April 2024 Heat Map
Seeking Alpha
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
The Motley Fool
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
Zacks Investment Research
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
Zacks Investment Research
About Astrazeneca PLC
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Cap:
|
Volume (24h):